Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Immuron welcomes launch of Travelan on Amazon US

July 26, 2023 at 14:45 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Immuron Ltd (NASDAQ: IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US.

Travelan is known to protect against the onset of travellers’ diarrhea (TD), the most common illness reported by travellers.

By launching directly onto Amazon US he says it gives consumers across the US the convenience to purchase Travelan with the ease of a click.

In other news, Immuron recently announced it has enrolled the first cohort of 30 participants into its Travelan® clinical study.

This Phase 2 trial aims to test Travelan®'s safety and its ability to protect against infection, compared to a placebo, in a controlled human infection model.

It is also examining a dosing regimen for Travelan® more suited to the US military.

Dosing should complete early next month, with headline results from the clinical trial expected in the first half of 2024.